Nationwide Fund Advisors continued to hold its stake in shares of Teligent, Inc. (NASDAQ:TLGT) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 23,779 shares of the company’s stock at the close of the second quarter. Nationwide Fund Advisors’ holdings in Teligent were worth $218,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Parkwood LLC bought a new position in shares of Teligent in the second quarter worth approximately $112,000. UBS Asset Management Americas Inc. bought a new position in Teligent during the first quarter valued at approximately $170,000. Renaissance Technologies LLC bought a new position in Teligent during the first quarter valued at approximately $198,000. American International Group Inc. lifted its position in Teligent by 7.1% during the first quarter. American International Group Inc. now owns 25,488 shares of the company’s stock valued at $199,000 after purchasing an additional 1,680 shares during the period. Finally, Aperio Group LLC bought a new position in Teligent during the second quarter valued at approximately $256,000. Hedge funds and other institutional investors own 65.85% of the company’s stock.
A number of research analysts recently weighed in on TLGT shares. Canaccord Genuity started coverage on shares of Teligent in a research report on Monday, July 31st. They set a “buy” rating and a $11.00 price objective on the stock. BidaskClub downgraded shares of Teligent from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 1st. Zacks Investment Research upgraded shares of Teligent from a “strong sell” rating to a “hold” rating in a research report on Friday, October 13th. TheStreet downgraded shares of Teligent from a “c-” rating to a “d+” rating in a research report on Wednesday, November 1st. Finally, Deutsche Bank AG lowered their price objective on shares of Teligent from $9.00 to $8.00 and set a “hold” rating on the stock in a research report on Monday, August 14th. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $7.33.
Teligent, Inc. (TLGT) opened at $3.51 on Wednesday. Teligent, Inc. has a 52-week low of $2.82 and a 52-week high of $9.54. The company has a debt-to-equity ratio of 2.23, a current ratio of 3.28 and a quick ratio of 3.71.
Teligent (NASDAQ:TLGT) last issued its quarterly earnings data on Monday, November 6th. The company reported ($0.08) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.01) by ($0.07). The company had revenue of $13.65 million for the quarter, compared to the consensus estimate of $19.12 million. Teligent had a negative net margin of 16.95% and a negative return on equity of 6.51%. The firm’s revenue for the quarter was down 15.5% on a year-over-year basis. During the same quarter last year, the company earned $0.01 EPS. analysts expect that Teligent, Inc. will post -0.13 earnings per share for the current year.
Teligent Company Profile
Teligent, Inc is a specialty generic pharmaceutical company. Under the Company’s own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2016.
Want to see what other hedge funds are holding TLGT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teligent, Inc. (NASDAQ:TLGT).
Receive News & Ratings for Teligent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent Inc. and related companies with MarketBeat.com's FREE daily email newsletter.